



**FOR IMMEDIATE RELEASE**

March 3, 2022

## **Vesey Street Capital Partners Announces the Addition of Dr. Amy Grogg to its Strategic Advisory Board**

*Noted life sciences services executive adds to VSCP network of healthcare services industry experts*

Vesey Street Capital Partners (“VSCP”) today announced that it has added Dr. Amy Grogg to its Strategic Advisory Board. Dr. Grogg is a nationally recognized expert in life science pharmaco-economics, health outcomes, quality of life, and commercialization services, with a 25 year record of success as an executive both at AmerisourceBergen (“ABC”) and Johnson & Johnson. While at ABC, Dr. Grogg developed strategies to advance the company’s leadership in the pharmaceutical services industry and position it as the preferred commercialization partner for pharmaceutical manufacturers. Among other roles, she served as President of AmerisourceBergen Consulting Services, where she led the growth of a portfolio of companies that included Xcenda, a market-leading global health outcomes and medical access consulting organization; Innomar Strategies, Canada’s leading commercialization services firm for specialty pharmaceuticals; and Lash Group, the U.S. leader in patient support services. Additionally, she held operational responsibility for CenterX, a healthcare services company whose digital tools enhance the prescribing experience to improve patient outcomes and provider workflow, and Cubixx Solutions, an innovative pharmaceutical inventory management solutions company. Before joining AmerisourceBergen, Dr. Grogg spent more than a decade in the pharmaceutical industry, primarily at Johnson & Johnson, where she led teams that were responsible for all health economic, quality of life, and patient-reported outcomes research studies for all of the company’s marketed products in the United States. Dr. Grogg received her Doctor of Pharmacy degree from Mercer University and completed a two-year fellowship in pharmaco-economics at Sandoz Pharmaceuticals Corporation and the University of South Carolina.

“We are extremely excited to have Amy expand her partnership with us,” noted Adam Feinstein, Vesey Street Capital Partners’s Founding Partner. “She has been a great contributor already on one of our company boards, and I am looking forward to having her work more with us and our management teams to identify and explore ways to create and add value in the evolving market of life sciences solutions and services.” “Simply put – Amy is a pharma market dynamo,” added Larry Marsh, a VSCP General Partner. “I have had the pleasure of working with her for much of the past decade, and am excited to expand our conversations together, and to further discuss market opportunities with our current and future stakeholders. “



“I am honored and extremely pleased to join the Vesey Street Capital Partners Strategic Advisory Board,” noted Grogg. “I have been very impressed with VSCP’s exceptional team-oriented culture, as well as their sector expertise and direct industry experience, and I have seen first-hand VSCP’s extremely collaborative style in working with their portfolio companies’ management teams to help grow value.”

“We are in times of almost unprecedented change and opportunity in life science clinical trial and commercialization services. I very much look forward to working with VSCP and with their current and future portfolio companies in this sector to help provide advice, insights, and perspective to help them grow and expand their healthcare solutions in the coming years.”

#### **ABOUT VESEY STREET CAPITAL PARTNERS**

Vesey Street Capital Partners is a private equity firm with substantial and differentiated expertise, specializing in buyouts of lower middle-market healthcare services businesses. VSCP invests on behalf of a wide array of Limited Partners, including asset management firms, family offices, pension funds, and other institutional investors. With over 100 combined years of analyzing and investing in healthcare services companies, VSCP possesses unparalleled industry knowledge and extensive relationships with industry executives and luminaries. Specifically, VSCP invests in lower middle-market businesses that provide services to hospitals, physician groups, payors, and life sciences companies and are focused on reducing costs, enhancing efficiency, and driving quality of care. Since its inception, VSCP has consummated 23 transactions across eight platform businesses and has deployed over \$600 million of equity capital. For more information, please visit [www.vscpllc.com](http://www.vscpllc.com).

**Media Contact:**

Tiffany Visconti, Investor Relations Analyst

Vesey Street Capital Partners  
The Pearline House  
428 Greenwich Street  
New York, NY 10013  
Email: [tiffany@vscpllc.com](mailto:tiffany@vscpllc.com)